Falcon Real World Evidence Registry
Recruiting
This is a multi-site registry of patients receiving the Exact Sciences Multicancer Early Detection (MCED) test.
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
05/30/2025
Locations: Endeavor Health, Evanston, Illinois +1 locations
Conditions: Cancer
Perspectives on Spinal Manipulative Therapy for Low Back Pain
Recruiting
The goal of this study is to better understand how the thoughts and beliefs of patients with low back pain and their physical therapist influence how much patients benefit from physical therapy. Participants will receive physical therapy as determined by their physical therapist including spinal manipulative therapy, exercise, and education. Participants with low back pain and their physical therapists will complete forms about their thoughts and beliefs about low back pain and treatment.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/30/2025
Locations: University of Florida, Gainesville, Florida
Conditions: Low Back Pain
Eating Disorders Genetics Initiative 2
Recruiting
The overarching intention of the Eating Disorder Genetics Initiative 2 (EDGI2) is to increase sample size, diversity, and eating disorder phenotypes. The investigators are enrolling 20,000 new participants with anorexia nervosa (AN), bulimia nervosa (BN), binge-eating disorder (BED), avoidant/restrictive food intake disorder (ARFID), and controls in the US, Mexico, Australia, New Zealand, Sweden, and Denmark. A primary study goal is to enroll at least 30% of participants from underrepresented gr... Read More
Gender:
ALL
Ages:
Between 12 years and 99 years
Trial Updated:
05/30/2025
Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina +4 locations
Conditions: Anorexia Nervosa, Bulimia Nervosa, Binge-Eating Disorder, Avoidant Restrictive Food Intake Disorder
Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease
Recruiting
This research study is designed to assess the prevalence of specific antibodies and inflammatory cytokines in adult and pediatric participants with CGD.
Gender:
ALL
Ages:
All
Trial Updated:
05/30/2025
Locations: Home-based telemedicine, Montgomery, Alabama +51 locations
Conditions: Chronic Granulomatous Disease (CGD)
Feasibility and Plausible Effectiveness of a Lifestyle Intervention in Kidney Transplant Recipients (HEAL)
Recruiting
The goal of this clinical trial is to learn whether if it is feasible to implement a study of patients receiving kidney transplantation, to learn if these patients will complete selective outcomes measurements, and to examine if a lifestyle intervention may assist with preventing weight gain compared to standard medical care. The main questions it aims to answer are: * Is it feasible to recruit and retain patients who have undergone kidney transplantation into a study to compare standard medica... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Kidney Transplant, Overweight or Obese Adults, Glucose Control
A Single-arm, Pivotal Study to Evaluate Acute Device and Technical Success of the CGuard Prime Carotid Stent System When Used in Conjunction to the ENROUTE Transcarotid Neuroprotection System in Patients Undergoing Carotid Artery Stenting Via the Transcarotid Artery Revascularization Approach
Recruiting
The objective of this study is to evaluate acute device and technical success of the CGuard Prime™ Carotid Stent System (80cm) when used in conjunction with the Enroute NPS during Transcarotid Artery Revascularization procedures in the treatment of carotid artery stenosis in spatients at high risk for adverse events from carotid endarterectomy.
Gender:
ALL
Ages:
Between 18 years and 79 years
Trial Updated:
05/30/2025
Locations: UC Davis Health, Sacramento, California +7 locations
Conditions: Carotid Artery Diseases
Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation
Recruiting
The study aims to compare the experiences, including injection-related reactions (IRRs) of patients newly receiving ofatumumab to those starting to receive ocrelizumab SC formulation
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
05/30/2025
Locations: Novartis Investigative site, East Hanover, New Jersey
Conditions: Multiple Sclerosis
The Impact of Heavy Alcohol Use on Saliva and Oral Health
Recruiting
Background: People with alcohol use disorder (AUD) have a higher rate of dental and gum disease. Poor oral health can increase the risk of other diseases, such as diabetes and stroke. Researchers want to learn more about how to identify developing inflammation in the mouth. They also want to know how improved oral health education and behaviors can affect inflammation in people with AUD. Objective: This study has 2 goals: (1) to test the usefulness of a new questionnaire about oral health and... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/30/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Alcohol Use Disorder, Alcohol Dependence
Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients
Recruiting
Background: Autoimmune lymphoproliferative syndrome (ALPS) is a rare disorder of the immune system caused by a mutation in the FAS gene. In ALPS, the body stores too many germ-fighting cells called lymphocytes. This can lead to an enlarged spleen and lymph nodes. Current treatments for ALPS can have many adverse effects. Better treatments for ALPS are needed. Objective: To test a study drug (soquelitinib) in people with ALPS. Eligibility: People aged 16 years and older with ALPS. Design:... Read More
Gender:
ALL
Ages:
Between 16 years and 120 years
Trial Updated:
05/30/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland +2 locations
Conditions: Autoimmune Lymphoproliferative Syndrome
Activity Coaching During Pelvic Radiation Therapy
Recruiting
Research has shown that for women who are undergoing pelvic radiation therapy, fatigue is a common side effect. Fatigue that occurs during radiation therapy can make it harder to perform daily living activities. While there are studies that recommend exercise as a treatment for fatigue in cancer patients and survivors, there are currently no studies that focus on the role of exercise for women undergoing pelvic radiation therapy. The purpose of this study is to see if incorporating an activity c... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: Inova Schar Cancer Institute - Alexandria, Alexandria, Virginia +3 locations
Conditions: Radiation Therapy, Gynecologic Cancer, Exercise Therapy
Pain Reprocessing Therapy in Post-Operative Knee Pain
Recruiting
The goal of this clinical trial is to learn whether Pain Reprocessing Therapy (PRT) can help adults with knee pain after knee replacement surgery. The study is comparing PRT to usual care (the regular treatment people get after surgery) to see which works better for relieving pain. The main questions the study aims to answer are: 1. Does PRT help lower pain in people who have chronic knee pain after knee surgery? 2. How do the effects of PRT compare with usual care in terms of pain relief and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado +1 locations
Conditions: Pain, Chronic, Knee Pain Chronic
A Postmarketing Study of Lecanemab in South Korean Participants With Alzheimer's Disease
Recruiting
The primary purpose of this study is to evaluate safety of lecanemab in the real-world clinical setting as reported by events of amyloid-related imaging abnormalities (ARIA)-edema (ARIA-E), ARIA-hemosiderin deposition (ARIA-H), symptomatic ARIA-E, symptomatic ARIA-H, and intracerebral hemorrhage (ICH) greater-than 1 centimeter (cm) in participants treated with lecanemab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: Eisai Trial Site #1, Nutley, New Jersey
Conditions: Alzheimer's Disease